Target intelligence / Profile preview

Cyclin G-associated kinase (GAK)

Target
GAK
Molecular classification
Enzyme, Serine/threonine kinase, Protein kinase, Numb-associated kinase (NAK) family, J-domain protein (co-chaperone)
01

Overview

Cyclin G-associated kinase (GAK) is a multifunctional serine/threonine kinase that is a member of the numb-associated kinase (NAK) family and encoded by the GAK gene in humans[1][2][3][5]. It serves as a critical regulator of clathrin-mediated vesicle trafficking by acting as a cofactor for heat shock cognate 70 (Hsc70) in the uncoating of clathrin-coated vesicles—a process essential for receptor recycling and intracellular signaling[4][5][7]. GAK phosphorylates the μ chain of clathrin adaptor proteins AP1 and AP2 and mediates vesicle trafficking not only at the plasma membrane but also at the trans-Golgi network[7]. In addition to its cytoplasmic role, GAK is crucial for mitotic progression through regulation of centrosome maturation and spindle assembly, and its loss leads to severe defects in embryonic and adult tissue viability[5][7]. GAK is also associated with disease: risk variants near its gene locus are linked to Parkinson’s disease, and its inhibition is a key safety concern in kinase inhibitor therapy, especially in lung cancer treatment with EGFR inhibitors such as gefitinib[2][5].

Other names
GAKDnaJ homolog subfamily C member 26DNAJC26Auxilin-22.7.11.1 (Enzyme Commission number)
02

Mechanism of action

Kinase inhibition (ATP-competitive inhibition) Inhibition of clathrin-mediated endocytosis by blocking vesicle uncoating and signaling protein trafficking

03

Biological functions

Clathrin-mediated endocytosisClathrin-coated vesicle traffickingRegulation of clathrin assembly/disassemblyReceptor recycling and intracellular traffickingMitotic progression (centrosome maturation and spindle formation)Cell cycle regulationATP binding
04

Disease associations

Neurodegenerative disease (notably Parkinson’s disease risk association)Cancer (indirectly via relevance to receptor trafficking and cell cycle)Developmental disorders (essential for embryonic development and adult tissue viability)
05

Safety considerations

Essential cellular function (inhibition may cause severe toxicity, e.g., fatal respiratory dysfunction in animal models)Off-target toxicity when targeted by kinase inhibitors such as gefitinib
06

Interacting drugs

1 more in the full profile.

07

Biomarkers

Genetic variants in GAK/DGKQ region as risk factors for Parkinson’s disease

Beyond the preview

Go deeper on Cyclin G-associated kinase (GAK).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cyclin G-associated kinase (GAK).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call